Andreas Pinter

48PUBLICATIONS

124CO-AUTHORS

Innate immunityPharmacogenomicsEpidemiological modellingMajor global burdens of diseaseMedical biotechnology diagnostics (incl. biosensors)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (48)

Sort by Publication Date:

|May 23, 2026

Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.

|Dec 10, 2025

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.

Joseph F Merola, Lyn Guenther, Charles Lynde

|Nov 28, 2025

Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany.

Luise Heinrich, Thomas Birkner, Susanne Abraham

|Apr 14, 2025

A Novel Epidermis Model Using Primary Hidradenitis Suppurativa Keratinocytes.

Isabel Haferland, Andreas Pinter, Tanja Rossmanith

|Jan 14, 2025

Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database.

Andreas Pinter, Marcus Schulte, Nils Kossack

|Nov 22, 2024

Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.

Joseph F Merola, Alice B Gottlieb, Andreas Pinter

Pageof 8

Frequent Collaborators

Matthias Augustin

Melinda Gooderham

Knut Schäkel

Kristian Reich

Adam Reich

Antonio Costanzo

Ulrich Mrowietz

Andreas Wollenberg

Kim A Papp

Linda Stein Gold

Frequent Collaborators

Matthias Augustin

Melinda Gooderham

Knut Schäkel

Kristian Reich